RVMDW supply chain intelligence for Revolution Medicines, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Revolution Medicines, Inc. (RVMDW) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | 72% | o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cau… |
| BBIO | BridgeBio Pharma, Inc. | 72% | Reciprocal relationship from BBIO graph: Reciprocal relationship from RVMDW graph: o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associ… |
| BMY | Bristol-Myers Squibb Company | 72% | o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cau… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from BMY graph: Reciprocal relationship from RVMDW graph: o the type, complexity and novelty … |
| BMYMP | Bristol-Myers Squibb Co | 72% | o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cau… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from RVMDW graph: o the type, complexity and novelty of the program, and often can be several years or more per program. Delays assoc… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from RVMDW graph: o the type, complexity and novelty of the program, and often can be several years or more per program. Delays assoc… |
| NVSEF | Novartis AG | 72% | o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cau… |
| RLAY | Relay Therapeutics, Inc. | 72% | o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cau… |
| RLAY | Relay Therapeutics, Inc. | 72% | Reciprocal relationship from RLAY graph: Reciprocal relationship from RVMDW graph: o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associ… |
| SNYNF | Sanofi | 72% | ication The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimbur… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from RVMDW graph: ication The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant … |
| TCRT | Alaunos Therapeutics, Inc. | 72% | Reciprocal relationship from TCRT graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from TCRT graph: Reciprocal relationship from RVMDW graph: o the type, complexity and novelt… |
| TCRT | Alaunos Therapeutics, Inc. | 72% | o the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cau… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | 72% | the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or operating guidance we may provide. Ri… |
| BBIO | BridgeBio Pharma, Inc. | 72% | Reciprocal relationship from BBIO graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from RVMDW graph: the price of our common stock cou… |
| BMY | Bristol-Myers Squibb Company | 72% | the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or operating guidance we may provide. Ri… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from RVMDW graph: the price of our common stock could decline substantially. Such a stock price decline could occur even when we have m… |
| BMYMP | Bristol-Myers Squibb Co | 72% | the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or operating guidance we may provide. Ri… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from RVMDW graph: the price of our common stock c… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from RVMDW graph: the price of our common stock c… |
| NVSEF | Novartis AG | 72% | the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or operating guidance we may provide. Ri… |
| RLAY | Relay Therapeutics, Inc. | 72% | the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or operating guidance we may provide. Ri… |
| RLAY | Relay Therapeutics, Inc. | 72% | Reciprocal relationship from RLAY graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from RLAY graph: Reciprocal relationship from RVMDW graph: the price of our common stock cou… |
| SNYNF | Sanofi | 72% | ed the amendment consists of two separate contracts under ASC 842. One contract is related to a new right-of-use asset for the 800 Building, which is being accounted for as an operating lease, and th… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from SN… |
| TCRT | Alaunos Therapeutics, Inc. | 72% | Reciprocal relationship from TCRT graph: Reciprocal relationship from RVMDW graph: the price of our common stock could decline substantially. Such a stock price decline could occur even when we have … |
| TCRT | Alaunos Therapeutics, Inc. | 72% | the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or operating guidance we may provide. Ri… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RVMDW-DEBT-12303 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| RVMDW-DEBT-12302 | Warrants outstanding: 95422000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| TCRT | Alaunos Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| BBIO | BridgeBio Pharma, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| NVSEF | Novartis AG | 100.00 | 1 | ['customer', 'supplier'] |
| BNBX | BNB Plus Corp. | 50.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 50.00 | 2 | |
| DNTH | Dianthus Therapeutics, Inc. | 50.00 | 2 | |
| SYRE | Spyre Therapeutics, Inc. | 50.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 50.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 50.00 | 2 | |
| ERAS | Erasca, Inc. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 50.00 | 2 | |
| CLDX | Celldex Therapeutics, Inc. | 50.00 | 2 | |
| GERN | Geron Corporation | 50.00 | 2 |